

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE
DRUG UTILIZATION REVIEW BOARD (DURB) MEETING**

March 18, 2014

Georgia Department of Community Health

This list may change at any time. As previously posted, if a supplemental rebate class is not listed below, the class will be reviewed at the June 5th DURB Meeting. The manufacturers that presented at the February Manufacturers' Forum will not need to present again at the May Manufacturers' Forum. Please check back frequently for updates.

New Drugs for Review

Actemra[®] Subcutaneous

Gilotrif[™]

Injectafer[™]

Mekinist[™]

Tafinlar[®]

Tivicay[®]

Therapeutic Class for Review

Direct Inhibitors for Hepatitis C – Incivek[®], Olysio[™], Sovaldi[™], Victrelis[®]

Supplemental Rebate Classes for Review

Analgesics, Opioids

Antianginal Agents

Antibiotics, Inhaled for Cystic Fibrosis

Antidiabetics, Insulins

Antidiabetics, Non-insulins

Antihyperlipidemics

Antivirals, Antiretrovirals

Antivirals, Hepatitis Agents

Biologic Immunomodulators

Cephalosporins, Oral
Corticosteroids, Oral
Dermatologics, Antiinflammatory
Dermatologics, Antipsoriatics
Dermatologics, Corticosteroids
Dermatologics, Scabicides/Pediculocides
Growth Hormones
Multiple Sclerosis (MS) Agents
Multivitamins, Prenatal
Nasal Antiallergics
Nasal Steroids
Ophthalmics, Adrenergics
Ophthalmics, Antiallergics
Ophthalmics, Antiinfectives
Ophthalmics, Beta Blockers
Ophthalmics, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Ophthalmics, Prostaglandins
Ophthalmics, Steroids
Otic Antiinfectives
Phosphate Binders
Smoking Deterrents
Urinary Antiinfectives

Urinary Antispasmodics
Urinary Prostatic Hypertrophy

This list may change at any time. As previously posted, if a supplemental rebate class is not listed above, the class will be reviewed at the June 5th DURB Meeting. The manufacturers that presented at the February Manufacturers' Forum will not need to present again at the May Manufacturers' Forum. Please check back frequently for updates.